Skip to main content

Dr Paul Callaghan

Imaging Neurophysiologist

Role at ANSTO

Paul applies PET/CT and SPECT/CT multimodal molecular imaging techniques for investigating animal models of neurological and psychiatric disease.


After graduating with a B.Sc. (Hons.) from the University of Adelaide, Paul commenced a PhD jointly between the University of Adelaide and University of Texas Health Science Center at San Antonio, USA.

This work involved understanding the acute and long term pharmacology of the substituted amphetamine ("Ecstasy") p-methoxyamphetamine (PMA or 'Death'). Subsequently, Paul worked at Flinders University investigating novel autonomic neural pathways involved in neuroinflammation (pain).

Prior to working at ANSTO, he was at the University of Sydney, investigating the neurochemistry underlying long term behavioural changes in social anxiety produced by the substituted amphetamines, methamphetamine ('ice') and MDMA ('ecstasy').

Research interests and areas of expertise

Paul’s expertise lies in PET/SPECT longitudinal imaging, monoamine pharmacology, drug abuse, in vivo voltammetry, neuroanatomy, in vivo and in vitro pharmacological models, quantitative autoradiography, and immunohistochemistry.

Qualifications & Achievements

  • Postdoctoral Fellow, the University of Sydney
  • Ph.D. at the University of Adelaide
  • B.Sc.(Hons.) at the University of Adelaide
  • Paul is a member of the Society for Neuroscience (SFN)